Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2009-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.9.1.9PMID 19102665
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada

  2012cited by this paper
• Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

  2012cited by this paper
• Long-Acting Injectable Risperidone for the Treatment of Schizophrenia

  2012cited by this paper
• Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis

  2012cited by this paper
• Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA

  2012cited by this paper
• Olanzapine pamoate: a stick in time?

  2009cited by this paper
• Impact of risperidone long acting injection on resource utilization in psychiatric secondary care

  2008cited by this paper
• Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine

  2008cited by this paper
• PMH58 IMPROVEMENT IN PERSONAL AND SOCIAL FUNCTIONING IN SCHIZOPHRENIA PATIENTS TREATED WITH RISPERIDONE LONG ACTING INJECTION): 6-MONTH RESULTS FROM E-STAR

  2008cited by this paper
• Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine.

  2008cited by this paper
• Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset Psychosis: A Preliminary Study

  2008cited by this paper
• An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia.

  2008cited by this paper
• Frequently relapsing bipolar disorder: Evidence for an effective treatment

  2008cited by this paper
• New generation antipsychotic drugs and compliance behaviour

  2008cited by this paper
• Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months.

  2008cited by this paper
• A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia.

  2008cited by this paper
• Focal Gray Matter Changes in Schizophrenia across the Course of the Illness: A 5-Year Follow-Up Study

  2007cited by this paper
• Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

  2007cited by this paper
• Treatment Adherence and Long-Term Outcomes

  2007cited by this paper
• Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia.

  2007cited by this paper
• Neuroprotection: A New Strategy in the Treatment of Schizophrenia

  2007cited by this paper
• Switching to Long-Acting Injectable Risperidone is Beneficial with Regard to Clinical Outcomes, Regardless of Previous Conventional Medication in Patients with Schizophrenia

  2007cited by this paper
• Thirty‐five months experience of risperidone long‐acting injection in a UK psychiatric service including a mirror‐image analysis of in‐patient care

  2007cited by this paper
• Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.

  2007cited by this paper
• The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia.

  2007cited by this paper
• Usefulness of long-acting injectable risperidone during 12-month maintenance therapy of bipolar disorder.

  2007cited by this paper
• Acute bipolar mania: a systematic review and meta‐analysis of co‐therapy vs. monotherapy

  2007cited by this paper
• A 6‐month randomized open‐label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in patients with bipolar disorder

  2007cited by this paper
• Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone

  2007cited by this paper
• A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.

  2006cited by this paper
• Treatment of Schizophrenia With Long-Acting Fluphenazine, Haloperidol, or Risperidone

  2006cited by this paper
• Risperidone long‐acting injection in practice – more questions than answers?

  2006cited by this paper
• Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.

  2006cited by this paper
• Long-acting risperidone: focus on safety.

  2006cited by this paper
• Health resource utilization associated with switching to risperidone long‐acting injection

  2006cited by this paper
• Serum concentrations of risperidone and 9‐OH risperidone following intramuscular injection of long‐acting risperidone compared with oral risperidone medication

  2006cited by this paper
• Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone

  2006cited by this paper
• A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder.

  2006cited by this paper
• A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study.

  2006cited by this paper
• Clinical experience and management considerations with long-acting risperidone

  2006cited by this paper
• Long-Acting Injectable Risperidone Compared with Zuclopenthixol in the Treatment of Schizophrenia with Substance Abuse Comorbidity

  2006cited by this paper
• Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials.

  2006cited by this paper
• Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia.

  2005cited by this paper
• Second-Generation (Atypical) Antipsychotics and Metabolic Effects

  2005cited by this paper
• Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder

  2005cited by this paper
• Hospitalization Rates in Patients During Long-Term Treatment With Long-Acting Risperidone Injection

  2005cited by this paper
• Long-acting risperidone in stable patients with schizoaffective disorder

  2005cited by this paper
• Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone

  2005cited by this paper
• Focus on protein kinase A and protein kinase C, critical components of signal transduction system, in mood disorders and suicide.

  2005cited by this paper
• Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year.

  2005cited by this paper
• Direct transition to long-acting risperidone - analysis of long-term efficacy

  2005cited by this paper
• Ten year longitudinal study of neuropsychological functioning subsequent to a first episode of schizophrenia.

  2005cited by this paper
• Remission in schizophrenia: proposed criteria and rationale for consensus.

  2005cited by this paper
• Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies

  2005cited by this paper
• Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.

  2005cited by this paper
• Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration.

  2005cited by this paper
• Risperidone plasma levels, clinical response and side–effects

  2005cited by this paper
• Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

  2005cited by this paper
• Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable

  2005cited by this paper
• Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.

  2005cited by this paper
• Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine

  2005cited by this paper
• A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.

  2005cited by this paper
• Pharmacokinetic Profile and Clinical Efficacy of Long-Acting Risperidone

  2005cited by this paper
• Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

  2005cited by this paper
• An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.

  2005cited by this paper
• Remission in schizophrenia: Results from a 1-year study of long-acting risperidone injection.

  2005cited by this paper
• Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

  2004cited by this paper
• Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.

  2004cited by this paper
• Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

  2004cited by this paper
• Efficacy and safety of long‐acting risperidone in elderly patients with schizophrenia and schizoaffective disorder

  2004cited by this paper
• Clinical review of a long-acting, injectable formulation of risperidone.

  2004cited by this paper
• Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

  2004cited by this paper
• Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia.

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement.

  2004cited by this paper
• Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

  2004cited by this paper
• Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia.

  2004cited by this paper
• Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.

  2004cited by this paper
• Healthcare resource utilization during 1‐year treatment with long‐acting, injectable risperidone

  2004cited by this paper
• Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.

  2004cited by this paper
• Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone

  2004cited by this paper
• Consensus development conference on antipsychotic drugs and obesity and diabetes.

  2004cited by this paper
• Impractical features of long-acting risperidone.

  2004cited by this paper
• Impractical Features of Long-Acting Risperidone

  2004cited by this paper
• Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics

  2004cited by this paper
• Academic highlights: guidelines for the use of long-acting injectable atypical antipsychotics.

  2004cited by this paper
• Partial compliance and patient consequences in schizophrenia: our patients can do better.

  2003cited by this paper
• Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.

  2003cited by this paper
• Increased suicide attempt rate among patients interrupting use of atypical antipsychotics

  2003cited by this paper
• On the path to recovery: patients' experiences of treatment with long-acting injections of antipsychotic medication.

  2003cited by this paper
• A systematic review of atypical antipsychotic drugs in schizophrenia.

  2003cited by this paper
• Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

  2003cited by this paper
• Nonhuman primate studies of fear, anxiety, and temperament and the role of benzodiazepine receptors and GABA systems.

  2003cited by this paper
• Clinical guidelines: Dosing and switching strategies for long-acting risperidone.

  2003cited by this paper
• Antipsychotic maintenance in schizophrenia: Partial compliance and clinical outcome

  2003cited by this paper
• The influence of risperidone on cognitive functions in schizophrenia.

  2003cited by this paper
• Long-acting risperidone: Prolonged-release injectable delivery of risperidone using medisorbò microsphere technology

  2003cited by this paper
• Long-Acting Injectable Antipsychotics in the Elderly

  2003cited by this paper
• Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics.

  2003cited by this paper
• Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study.

  2003cited by this paper
• Antipsychotic medication adherence: is there a difference between typical and atypical agents?

  2002cited by this paper

• The effectiveness of long-acting injectable risperidone in a population of psychiatric out-patients: 1-year naturalistic study.

  2025cites this paper
• Population Pharmacokinetics of Risperidone and Paliperidone in Schizophrenia: A Systematic Review

  2025cites this paper
• The pursuit of linear dosage in pharmacy: reservoir-based drug delivery systems from macro to micro scale

  2025cites this paper
• Piperidine-Based Nonfused Biheterocycles With C–N and C–C Coupling

  2017cites this paper
• Abnormal Trajectory of Intracortical Myelination in Schizophrenia Implicates White Matter in Disease Pathophysiology and the Therapeutic Mechanism of Action of Antipsychotics.

  2017cites this paper
• Efficacy, Safety, and Tolerability of RBP-7000 Once-Monthly Risperidone for the Treatment of Acute Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study

  2016cites this paper
• Population pharmacokinetic modeling and simulation to guide dose selection for RBP‐7000, a new sustained‐release formulation of risperidone

  2015cites this paper
• A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea

  2014influential citation
• The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal

  2014cites this paper
• Chronic administration of risperidone in a rat model of schizophrenia: a behavioural, morphological and molecular study.

  2013cites this paper
• Optimal needle insertion length for intramuscular injection of risperidone long-acting injectable (RLAI)

  2013cites this paper
• Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder.

  2013cites this paper
• The Cost Effectiveness of Long-Acting/Extended-Release Antipsychotics for the Treatment of Schizophrenia

  2013cites this paper
• Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: Alzheimer's and schizophrenia.

  2013cites this paper
• The Challenge of Adherence in Schizophrenia

  2013cites this paper
• Novel N-5-(acyloxyalkoxy)carbonyl prodrugs of olanzapine with physicochemical properties for extended-release

  2013cites this paper
• White matter dementia

  2012cites this paper
• Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia

  2012cites this paper
• A review of paliperidone palmitate

  2012cites this paper
• Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

  2012cites this paper
• Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia

  2012cites this paper
• THE IMPACT OF TREATMENT WITH RISPERIDONE LONG-ACTING INJECTION ON THE BELGIAN HEALTHCARE SYSTEM: RESULTS FROM A BUDGET IMPACT MODEL

  2012cites this paper
• The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving

  2012cites this paper
• Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

  2012cites this paper
• A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder

  2012cites this paper
• Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results

  2011cites this paper
• Biodegradable Polymers in Drug Delivery

  2011cites this paper
• Neuroglialpharmacology: white matter pathophysiologies and psychiatric treatments.

  2011cites this paper
• Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory.

  2011influential citation
• Risperidone long-acting injection as monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder

  2010cites this paper
• Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention

  2010cites this paper
• Prospective, Open Study of Long-Acting Injected Risperidone versus Oral Antipsychotics in 88 Chronically Psychotic Patients

  2010cites this paper
• EFFECTS OF COMBINED THERAPY WITH NIFEDIPINE AND MELATONIN ON HALOPERIDOL- INDUCED TARDIVE DYSKINESIA IN RATS

  2010cites this paper
• Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.

  2010cites this paper
• Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection

  2010cites this paper
• Chronic administration of risperidone to healthy rats: a behavioural and morphological study.

  2009cites this paper